Takeda (TAK)
18.45
-0.26 (1.39%)
Upcoming Events
Latest Headlines
Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley
September 4, 2026 6:59 AM - StreetInsider
Form 4 TAKEDA PHARMACEUTICAL For: Sep 02 Filed by: Plump Andrew Stewart
September 3, 2026 9:49 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
September 2, 2026 4:14 PM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet
September 2, 2026 8:12 AM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: Aug 28
August 31, 2026 6:59 AM - SEC Filing
FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
August 28, 2026 6:40 PM - StreetInsider
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
August 28, 2026 6:40 PM - BizWire
Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY7,600 at Citi
August 25, 2026 7:11 AM - StreetInsider
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 24, 2026 2:36 AM - BizWire
Form 4 TAKEDA PHARMACEUTICAL For: Aug 19 Filed by: Plump Andrew Stewart
August 21, 2026 4:30 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 18 Filed by: Greenway Nicola Deidre Petal
August 19, 2026 4:16 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
August 19, 2026 3:59 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
August 14, 2026 4:17 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Farajallah Awny Samaan Botros
August 12, 2026 9:54 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Ibrahim Ramy Riad Ahmed
August 12, 2026 9:54 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Pacheco Rhonda Janice
August 12, 2026 9:54 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Duprey Lauren Rusckowski
August 12, 2026 9:51 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Plump Andrew Stewart
August 12, 2026 9:51 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Pignagnoli Agosti Marcello
August 12, 2026 9:47 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Bitetti Teresa Marie
August 12, 2026 9:45 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Shannon Elaine Mary
August 12, 2026 9:43 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Ricci Gabriele
August 12, 2026 9:39 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Greenway Nicola Deidre Petal
August 12, 2026 9:29 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Kim Julie So-Young
August 12, 2026 9:27 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Platford Giles Richard
August 12, 2026 9:25 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Furney Natalie Anne Marie
August 12, 2026 9:24 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Greenway Nicola Deidre Petal
August 12, 2026 4:10 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Aug 11 Filed by: Shannon Elaine Mary
August 12, 2026 4:10 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Shannon Elaine Mary
August 10, 2026 4:31 PM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
August 6, 2026 5:17 PM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Aug 05
August 6, 2026 6:06 AM - SEC Filing
FDA approves Takeda's Orzeyful for narcolepsy type 1 in adults
August 5, 2026 6:10 PM - StreetInsider
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
August 5, 2026 6:10 PM - BizWire
Keros Therapeutics to receive $20M milestone from Takeda
July 30, 2026 4:01 PM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: Jul 30
July 30, 2026 6:05 AM - SEC Filing
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
July 30, 2026 2:37 AM - BizWire
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,800 at JPMorgan
July 29, 2026 8:47 AM - StreetInsider
Takeda psoriasis drug shows skin clearance in Phase 3 trials
July 16, 2026 6:00 PM - StreetInsider
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
July 16, 2026 6:00 PM - BizWire
Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello
July 13, 2026 6:27 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
July 13, 2026 6:26 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
July 13, 2026 6:26 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Furney Natalie Anne Marie
July 13, 2026 6:25 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Ricci Gabriele
July 13, 2026 6:25 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
July 13, 2026 6:25 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Shannon Elaine Mary
July 13, 2026 6:24 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Ibrahim Ramy Riad Ahmed
July 13, 2026 6:23 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Farajallah Awny Samaan Botros
July 13, 2026 6:23 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Pacheco Rhonda Janice
July 13, 2026 6:23 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
July 13, 2026 6:22 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
July 13, 2026 6:22 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Kim Julie So-Young
July 13, 2026 6:08 AM - SEC Filing
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
July 12, 2026 7:00 PM - BizWire
Form 6-K TAKEDA PHARMACEUTICAL For: Jul 09
July 9, 2026 6:03 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jul 08
July 8, 2026 6:03 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: GILLIS STEVEN
July 6, 2026 6:29 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: MARAGANORE JOHN
July 6, 2026 6:29 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Reed Kimberly A.
July 6, 2026 6:28 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Iijima Masami
July 6, 2026 6:14 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: BROUSSARD BRUCE D
July 6, 2026 6:12 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Stoffels Paulus
July 6, 2026 6:11 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kimura Koichiro
July 6, 2026 6:11 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Tsusaka Miki
July 6, 2026 6:10 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Miyabashira Asuka
July 6, 2026 6:10 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furuta Milano
July 6, 2026 6:09 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Platford Giles Richard
July 6, 2026 6:08 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Smoter Jennifer Marie
July 6, 2026 6:08 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ibrahim Ramy Riad Ahmed
July 6, 2026 6:07 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Greenway Nicola Deidre Petal
July 6, 2026 6:06 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Farajallah Awny Samaan Botros
July 6, 2026 6:06 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furney Natalie Anne Marie
July 6, 2026 6:05 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pacheco Rhonda Janice
July 6, 2026 6:05 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pignagnoli Agosti Marcello
July 6, 2026 6:05 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ricci Gabriele
July 6, 2026 6:04 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Shannon Elaine Mary
July 6, 2026 6:04 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Duprey Lauren Rusckowski
July 6, 2026 6:03 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Bitetti Teresa Marie
July 6, 2026 6:03 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kim Julie So-Young
July 6, 2026 6:02 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Plump Andrew Stewart
July 6, 2026 6:01 PM - SEC Filing
Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Kimura Koichiro
July 6, 2026 11:32 AM - SEC Filing
Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: BROUSSARD BRUCE D
July 6, 2026 11:32 AM - SEC Filing
Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Stoffels Paulus
July 6, 2026 11:32 AM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Macquarie
June 30, 2026 6:17 AM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 29
June 29, 2026 6:04 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 26
June 26, 2026 6:33 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
June 24, 2026 6:15 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
June 24, 2026 6:07 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
June 24, 2026 6:05 AM - SEC Filing
Takeda names Julie Kim as president and CEO after shareholder vote
June 24, 2026 3:14 AM - StreetInsider
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
June 24, 2026 3:05 AM - BizWire
Form IRANNOTICE TAKEDA PHARMACEUTICAL
June 17, 2026 6:32 AM - SEC Filing
Form 20-F TAKEDA PHARMACEUTICAL For: Mar 31
June 17, 2026 6:07 AM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,500 at Nomura/Instinet
June 16, 2026 7:12 AM - StreetInsider
Goldman Sachs Reiterates Neutral Rating on Takeda Pharmaceutical (4502:JP) (TAK)
June 16, 2026 12:22 AM - StreetInsider
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
June 15, 2026 12:00 PM - BizWire
Takeda's zasocitinib beats deucravacitinib in psoriasis study
June 11, 2026 7:00 AM - StreetInsider
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
June 11, 2026 7:00 AM - BizWire
FDA accepts Takeda's application for pediatric ENTYVIO treatment
June 9, 2026 4:30 PM - StreetInsider
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
June 9, 2026 4:30 PM - BizWire
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 09
June 9, 2026 6:10 AM - SEC Filing
Full Article List
